Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong
3 other identifiers
observational
600
1 country
5
Brief Summary
The true incidence and prevalence of NAFLD in Hong Kong has not been determined. The natural history of NAFLD is not well defined partly because of differences in the exclusion limit of alcohol and the required histological criteria between studies. NAFLD is previously believed to be a benign non-progressive condition, but it has since been determined that a subset of patients can progress to cirrhosis and even hepatocellular carcinoma. In fact in a recent histological review of NAFLD, fibrosis or liver cirrhosis was present in 15-50% of patients at index liver biopsy. The presence of obesity or type 2 diabetes mellitus are the strongest predictors of fibrosis. These same risk factors are also more common in patients with cryptogenic cirrhosis. Further evidence of the link between diabetes, obesity and NAFLD are mainly from the field of liver transplantation. In patients who underwent liver transplantation for cryptogenic liver cirrhosis, NAFLD recuured in a quarter of the hepatic allografts. The patients with recurrent NAFLD were more likely to be diabetic and had a higher body mass index (BMI) at the time of recurrent NAFLD. This suggests that NAFLD may have a significant role in the pathogenesis of crytogenic cirrhosis. Although NAFLD was initially described as a slowly progressive disease, there are emerging data which shows that it can progress rapidly. Liver failure has even been described in patients with NAFLD after bariatric surgery, and a recent report described 5 cases of subacute liver failure in obese middle aged females with NAFLD related cirrhosis. NAFLD can also affect the progression of other diseases as well. Hepatic steatosis related to visceral obesity is a major independent risk factor for fibrogenesis related to chronic HCV hepatitis. However, the prevalence of NAFLD and its interaction with chronic HBV, if any, is uncertain. This study aims to determine the prevalence of NAFLD in patients with unknown cause of hepatitis and to determine the histological fibrosis and inflammation in chronic HBV patients with NAFLD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2004
Typical duration for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2004
CompletedFirst Submitted
Initial submission to the registry
July 6, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2007
CompletedFirst Posted
Study publicly available on registry
December 19, 2007
CompletedDecember 17, 2008
June 1, 2008
July 6, 2007
December 15, 2008
Conditions
Keywords
Eligibility Criteria
You may qualify if:
- years old
- Gender: male and female
You may not qualify if:
- HBV patients and fatty liver HCV HIV
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hospital Authority, Hong Konglead
- The University of Hong Kongcollaborator
Study Sites (5)
Department of Medicine, Queen Mary Hospital
Hong Kong, China
Department of Pathology, Princess Margaret Hospital
Hong Kong, China
Department of Pathology, Queen Elizabeth Hospital
Hong Kong, China
Department of Pathology, Queen Mary Hospital
Hong Kong, China
Department of Pathology, Tuen Mun Hospital
Hong Kong, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
George K Lau, Dr
Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Study Design
- Study Type
- observational
- Sponsor Type
- OTHER GOV
Study Record Dates
First Submitted
July 6, 2007
First Posted
December 19, 2007
Study Start
June 1, 2004
Study Completion
December 1, 2007
Last Updated
December 17, 2008
Record last verified: 2008-06